Literature DB >> 10499641

Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.

M Nishiyama1, W Yamamoto, J S Park, R Okamoto, H Hanaoka, H Takano, N Saito, M Matsukawa, T Shirasaka, M Kurihara.   

Abstract

The synergistic mechanism of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination remains unclear, despite its substantial antitumor activity, which has been demonstrated clinically. To clarify the mechanism(s), we determined the sensitivity or resistance factors to either drug in seven gastrointestinal cancer cell lines and then analyzed the altered gene expression after different exposures to CDDP and 5-FU. At the basal gene expression level, glutathione S-transferase pi (GSTpi) expression correlated with the observed resistance to CDDP, whereas dihydropyrimidine dehydrogenase (DPD) and multidrug resistance-associated protein (MRP) expression was related to 5-FU resistance. GSTpi, DPD, and MRP expression increased in response to the respective drug, but they also increased in response to the other drug as well. Additionally, 5-FU revealed a drastically increased thymidylate synthase (TS) gene expression in 5-FU-resistant cells. However, the increasing actions of CDDP and 5-FU on GSTpi, DPD, MRP, and TS expression varied according to the exposure time, concentration, and schedule. A low concentration of CDDP (1 microg/ml, 30 min) followed by 5-FU (0.5 microg/ml, 72 h) was found to cause a less increased expression of DPD, MRP, GSTpi, and TS than either drug alone, thus resulting in synergistic cytotoxicity in 5-FU-resistant COLO201 and CDDP-resistant HCC-48 cells. The sequential combination of CDDP and 5-FU inhibited the growth of human normal renal proximal tubule cells by less than 20%. Low concentrations of CDDP followed by continuous exposure to 5-FU can repress increased gene expression related to both drug resistances, thereby being synergistically cytotoxic in human gastrointestinal cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499641

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma.

Authors:  Myeong Jun Song
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

3.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

4.  HPLC-based activity profiling of anti-hepatocellular carcinoma constituents from the Tibetan medicine, Caragana tibetica.

Authors:  Ping Song; Qiang Wang; Jing-Nan Lv; Chan Xu; Qin-Xiong Lin; Xin-Hua Ma; Mi Huang; Xin-Zhou Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

5.  Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.

Authors:  M Caro; A Font; S Comas; M Viciano; J Remon; P Céliz; J Robles; E Musulén; M J Sendrós; E Mesalles; J A Jiménez; J Boix; A Arellano; J Fernández-Llamazares
Journal:  Clin Transl Oncol       Date:  2016-02-08       Impact factor: 3.405

6.  Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer.

Authors:  Li Jiao; Melissa L Bondy; Manal M Hassan; David Z Chang; James L Abbruzzese; Douglas B Evans; Michael H Smolensky; Donghui Li
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

7.  Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.

Authors:  Beom Kyung Kim; Jun Yong Park; Hye Jin Choi; Do Young Kim; Sang Hoon Ahn; Ja Kyung Kim; Do Youn Lee; Kwang Hoon Lee; Kwang-Hyub Han
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-16       Impact factor: 4.553

Review 8.  Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.

Authors:  T Shirasaka; S Yamamitsu; A Tsuji; T Taguchi
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

9.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

10.  Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.

Authors:  Buyun Ma; Yanchun Wang; Xiumei Zhou; Panpan Huang; Rong Zhang; Tao Liu; Caixia Cui; Xinyuan Liu; Yigang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.